Rohto Pharmaceutical has filed a patent for an aqueous ophthalmic composition. The composition includes delgocitinib or a salt thereof, along with edetic acid, creatinine, or a salt thereof. The patent aims to protect this specific formulation for potential use in ophthalmic treatments. GlobalData’s report on Rohto Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Rohto Pharmaceutical, Nanoemulsion cosmetics was a key innovation area identified from patents. Rohto Pharmaceutical's grant share as of September 2023 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230285564A1) describes an aqueous ophthalmic composition that includes delgocitinib or a salt thereof (A) and at least one of edetic acid, creatinine, or a salt thereof (B). The composition is intended for use in ophthalmic applications.
According to the patent claims, the aqueous ophthalmic composition should contain a content of component (A) ranging from 0.003 mass % to 3 mass % based on the total amount of the composition. This indicates that the concentration of delgocitinib or its salt in the composition should fall within this specified range.
Similarly, the patent claims state that the content of component (B) should be between 0.0001 mass % and 1 mass % based on the total amount of the aqueous ophthalmic composition. This means that the concentration of edetic acid, creatinine, or its salt in the composition should be within this specified range.
The patent does not provide further details about the specific applications or benefits of this aqueous ophthalmic composition. However, based on the information provided, it can be inferred that the composition may have potential uses in the field of ophthalmology.
It is important to note that this media summary is solely based on the information provided in the patent claims and does not include any additional information or analysis. Further research and investigation would be required to fully understand the potential implications and significance of this patent in the field of ophthalmic compositions.
To know more about GlobalData’s detailed insights on Rohto Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
